vida: extract claims from 2024-xx-stanford-ibogaine-veterans-ptsd-n30

- Source: inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Trump's $50M ARPA-H ibogaine EO was driven by Stanford's 30-person uncontrolled pilot despite lacking Phase 3 evidence, demonstrating constituency-driven policy acceleration
+confidence: experimental
+source: Stanford University School of Medicine pilot study (n=30), Trump EO April 2026
+created: 2026-05-10
+title: Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+agent: vida
+sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
+scope: structural
+sourcer: Stanford University School of Medicine / CNN / NPR
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
+---
+
+# Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+
+The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.

domains/health/ibogaine-iv-magnesium-protocol-demonstrates-cardiac-risk-manageable-in-supervised-settings-addressing-primary-safety-barrier.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Stanford's use of intravenous magnesium as QT prolongation prophylaxis resulted in zero serious cardiac events across 30 participants, suggesting the fatal arrhythmia risk can be mitigated
+confidence: experimental
+source: Stanford University ibogaine study (n=30)
+created: 2026-05-10
+title: IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
+agent: vida
+sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
+scope: functional
+sourcer: Stanford University School of Medicine
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
+---
+
+# IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
+
+Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous magnesium specifically to protect cardiac rhythm, and all 30 participants were screened for cardiac risk factors before enrollment. The study reported zero serious cardiac events. While n=30 is too small to definitively establish safety, this represents the first published protocol demonstrating that ibogaine's cardiac risk may be manageable through prophylactic intervention and screening in a hospital-grade clinical environment. The IV magnesium approach is a clinical safety innovation that could enable Phase 3 trial design by addressing the primary regulatory safety concern. This shifts ibogaine from 'too dangerous to study' to 'requires specialized protocol' category, similar to how ketamine's dissociative effects required specialized clinical settings but didn't prevent FDA approval for depression.

entities/health/stanford-ibogaine-veterans-study.md

@@ -0,0 +1,36 @@
+---
+type: entity
+entity_type: research_program
+name: Stanford Ibogaine Veterans Study
+domain: health
+status: completed
+---
+
+# Stanford Ibogaine Veterans Study
+
+## Overview
+Stanford University School of Medicine pilot study investigating ibogaine for veterans with PTSD, traumatic brain injury, and/or substance use disorder.
+
+## Key Details
+- **Design**: n=30 veterans, uncontrolled pilot, overseas clinical setting (ibogaine is Schedule I in US)
+- **Innovation**: IV magnesium protocol for QT prolongation prophylaxis
+- **Primary outcome**: 1-month self-reported symptom reduction
+- **Results**: 88% PTSD reduction, 87% depression reduction, 81% anxiety reduction
+- **Safety**: Zero serious cardiac events with magnesium protocol
+
+## Evidence Limitations
+- No control group (no placebo comparison)
+- Single timepoint (1 month only, no durability data)
+- Non-representative population (veteran-specific)
+- Self-reported outcomes (expectancy bias risk)
+- Small sample size (n=30)
+
+## Policy Impact
+Despite evidence limitations, this study was specifically cited in Trump's April 2026 executive order allocating $50M in ARPA-H funding for ibogaine research in veterans. Ex-Navy SEALs and Special Operations veterans were present at EO signing.
+
+## Timeline
+- **2024** — Study published, first hospital-grade ibogaine protocol with cardiac safety measures
+- **2026-04** — Trump EO names ibogaine for veterans, $50M ARPA-H funding commitment
+
+## Significance
+Represents first peer-reviewed evidence that ibogaine's cardiac risk (QT prolongation) may be manageable in supervised clinical settings through prophylactic intervention. Also demonstrates how politically salient populations (veterans) can drive federal policy ahead of standard evidence hierarchies (Phase 3 trials).

inbox/archive/health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md

@@ -7,10 +7,13 @@ date: 2024-01-01
 domain: health
 secondary_domains: []
 format: research-summary
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [ibogaine, PTSD, veterans, TBI, clinical-research, psychedelic, opioid-addiction, cardiac-safety, Stanford, executive-order]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content